Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
3/26/24 | Praxis (PRAX) | PRAX-628 for Seizure Disorders (Epilepsy) | Subscribers Only | Subscribers Only | Subscribers Only |
3/25/24 | Axsome Therapeutics (AXSM) | AXS-12 for Narcolepsy | Subscribers Only | Subscribers Only | Subscribers Only |
3/21/24 | Roche (RHHBY) | Enspryng for Myasthenia Gravis (MG) | Subscribers Only | Subscribers Only | Subscribers Only |
3/20/24 | Acelyrin (SLRN) | VB421 for Thyroid Eye Disease (TED) | Subscribers Only | Subscribers Only | Subscribers Only |
3/19/24 | Merck (MRK) | V116 for Pneumococcal (Streptococcus pneumoniae) Vaccines (Antibacterial) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
12/26/23 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
12/31/23 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
02/16/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
02/16/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
02/29/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |